Trulieve Cannabis Corp.
No SEC Form 4 filings for $TRLV in the last 30 days.
See all $TRLV insider activity →Innovative Industrial Properties (IIPR) and Trulieve Cannabis (TRLV) reported higher Q2 profits. IIPR's revenue was $63.3M, AFFO per share $1.83. TRLV's revenue was $271M, EPS $0.11. Both stocks are up YTD, with TRLV +28%. They have strong balance sheets and shareholder-friendly policies, but face industry risks.
U.S. stock futures were flat ahead of PCE data and Micron's earnings. Boeing rose 3% after a $20B Navy contract, while Concentrix fell 11% on weak revenue and guidance. Moderna dropped 6.3% following a Citi downgrade. Trulieve Cannabis and Yiren Digital also moved on news.
Trulieve Cannabis (TRLV) shares fell 6.5% in pre-market trading after announcing a licensing deal with Connected Cannabis, which investors reassessed for costs and risks. CEO Kim Rivers' share sale plan and institutional rebalancing added pressure. Q2 revenue was $271M, down 10% YoY, with a net loss. Broader market conditions offered no support.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TRLV (Trulieve Cannabis Corp.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TRLV coverage spans market movers, corporate actions and earnings.
TRLV could experience price appreciation on the earnings turnaround and upcoming stock repurchase.
Licensing deal raises integration cost concerns.
The licensing agreement adds integration risk and the insider sell window adds pressure, likely driving the stock lower.
TRLV faces immediate downside as the regulatory delay undermines its growth expectations.
The new brand rights could boost revenue growth in Florida and eventually Texas, but Texas launch depends on regulatory approval.
AlphAI scores every news story that mentions TRLV with an AI model for sentiment and relevance, and aggregates insider trades from Trulieve Cannabis Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Innovative Industrial Properties (IIPR) and Trulieve Cannabis (TRLV) reported higher Q2 profits. IIPR's revenue was $63.3M, AFFO per share $1.83. TRLV's revenue was $271M, EPS $0.11. Both stocks are up YTD, with TRLV +28%. They have strong balance sheets and shareholder-friendly policies, but face industry risks.
3 min readU.S. stock futures were flat ahead of PCE data and Micron's earnings. Boeing rose 3% after a $20B Navy contract, while Concentrix fell 11% on weak revenue and guidance. Moderna dropped 6.3% following a Citi downgrade. Trulieve Cannabis and Yiren Digital also moved on news.
2 min readTrulieve Cannabis (TRLV) shares fell 6.5% in pre-market trading after announcing a licensing deal with Connected Cannabis, which investors reassessed for costs and risks. CEO Kim Rivers' share sale plan and institutional rebalancing added pressure. Q2 revenue was $271M, down 10% YoY, with a net loss. Broader market conditions offered no support.
1 min readMSOS, an ETF, and TRLV, one of its holdings, fell about 8-9% after hours as a federal judge paused a cannabis rescheduling case. The delay impacts investors' expectations for near-term changes to marijuana's legal status, which could affect the industry.
2 min readTrulieve Cannabis Corp. (TRLV) gained perpetual, royalty-free rights to cultivate, manufacture, and sell Alien Labs and Connected brands in Florida and Texas. The deal, contingent on Texas approval, includes genetics, trademarks, and know-how. Trulieve plans marketing campaigns and new product categories in Florida, with no set timeline. TRLV closed at $12.21 on Sept. 25, pre-announcement.
2 min readTrulieve Cannabis Corp. (TRLV) has been added to the S&P Total Market Index, S&P Completion Index, and related healthcare sub-indices. According to the company, this inclusion is expected to increase visibility, liquidity, and attract new institutional investors. Trulieve is a vertically integrated cannabis company operating in several U.S. states and listed on the NYSE.
2 min readTrulieve Cannabis (TRLV) and Cronos Group (CRON) have outperformed the S&P 500 in 2026, with both stocks up 27% through Sept. 18. Trulieve reported Q2 revenue of $271M, EBITDA of $98M, and $74M in free cash flow, while Cronos saw Q2 revenue rise 58% to $53M. Both companies face regulatory risks but have shown strong financial performance.
3 min readTrulieve Cannabis (TRLV) issued 10 million shares worth $55.5 million in an ESOP-related offering, causing a 6.5% stock price increase. The company also authorized a $50 million share buyback program. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside and others a more pessimistic outlook. Q2 2026 sales declined year over year, and net loss widened, keeping margin trends and capital deployment in focus.
3 min readU.S. stock futures rose late Monday, with Nasdaq up 0.01%, S&P 500 up 0.1%, and Dow up 0.05%. Investors focused on AI disruption, Fed rate path, and inflation data. ZIM agreed to a $4.2B acquisition by Hapag-Lloyd at $35 per share. AAPL announced a March 4 event, potentially featuring new products. TCNNF and DIS also drew attention.
2 min readTrulieve Cannabis Corp. (TRLV) completed its move from British Columbia to Delaware. The change, effective August 11, 2026, converted all outstanding shares and maintained the NYSE listing. Shareholder rights now follow Delaware law, with details in the proxy statement filed June 25, 2025.
1 min read
